Username
menu
Flowchart Overview
Search
count subtrees
List
Table
Oncology
18
ALLIANCE-MM1MDS-A01
Phase II
OPEN TO ACCRUAL
DAIICHI-SANKYO-DS3201-343
Phase I
OPEN TO ACCRUAL
DAIICHI-SANKYO-DS3939-077
Phase I/II
OPEN TO ACCRUAL
ECOG-EA4232
Phase III
OPEN TO ACCRUAL
ECOG-EA7222
Phase III
OPEN TO ACCRUAL
IIT-AKHTAR-CILTA-TALQ
Phase I
OPEN TO ACCRUAL
INCYTE-INCA035784-101
Phase I
OPEN TO ACCRUAL
INCYTE-INCA-34176-254
Phase II
OPEN TO ACCRUAL
LILLY-J2N-MC-JZNY
Phase IV
OPEN TO ACCRUAL
MERCK-MK2140-011-00
Phase II
OPEN TO ACCRUAL
MODERNA-MRNA-2808-P101
Phase I/II
OPEN TO ACCRUAL
NEOGENE-NT-112-301
Phase I
OPEN TO ACCRUAL
NEOGENE-NT-175-201
Phase I
OPEN TO ACCRUAL
STEMLINE-MEN2312-01
Phase I
OPEN TO ACCRUAL
SWOG-MM1OA-S03
Phase II
OPEN TO ACCRUAL
SWOG-MM1YA-S01
Phase II
OPEN TO ACCRUAL
TERREMOTO-TER-2013-C01
Phase I/II
OPEN TO ACCRUAL
TEVA-TV56278-ONC-10203
Phase I
OPEN TO ACCRUAL
Brain and Spine Cancers
Brain and CNS Mets
1
Glioma
Grade 2
2
Grade 3
2
Grade 4 (GBM)
3
Meningioma
Grade 1
Grade 2
1
Preventative, Supportive Care, and Wellness
1
Spine
Breast
2
IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
NEOGENE-NT-175-201
Phase I
OPEN TO ACCRUAL
Adjuvant
4
DCIS
Metastatic
4
Neo-Adjuvant
1
Preventative, Supportive Care, and Wellness
Cell Therapy Protocols
9
CARIBOU-CAMMOUFLAGE-CB-011A-MM
Phase I
OPEN TO ACCRUAL
CELGENE-GC-LTFU-001
Phase II/III
OPEN TO ACCRUAL
GRACELL-GC012F-CD19-BCMA-001
Phase I/II
OPEN TO ACCRUAL
GSK-3377794-LTFU
Phase I
OPEN TO ACCRUAL
IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
JNJ-MY4002-CARTINUE-LTFU
Phase IV
OPEN TO ACCRUAL
JUNO-017004-TRANSCEND-CLL
Phase I/II
OPEN TO ACCRUAL
NEOGENE-NT-112-301
Phase I
OPEN TO ACCRUAL
NEOGENE-NT-175-201
Phase I
OPEN TO ACCRUAL
Endocrine Cancers
Eye/Orbital Cancers
GI Cancers
1
TRANSTHERA-TT420C2308
Phase III
OPEN TO ACCRUAL
Anal
1
Biliary
2
1st Line
2nd Line +
2
Locally advanced
Colorectal
3
Colon stage I-III
1
Metastatic
3
1st Line
2nd Line
3rd Line +
Rectal stage I-III
1
Esophageal
4
Gastric
3
Liver/HCC
2
Extrahepatic Disease
1st Line
2nd Line +
Liver Metastases
w/o Extrahepatic Disease: Transplant Eligible
w/o Extrahepatic Disease: Transplant Ineligible
Adjuvant
Locally Advanced: Liver-directed Therapy Eligible
Neuroendocrine
2
Pancreas
3
Localized
Adjuvant
1
Neoadjuvant
2
Locally Advanced
1
Metastatic
2
1st Line
1
2nd Line +
1
Preventative, Supportive Care, and Wellness
Gynecologic Cancers
1
NEOGENE-NT-112-301
Phase I
OPEN TO ACCRUAL
Cervical
Primary
1
Recurrent
2
Endometrial
1
Primary
2
NRG-GY026
NRG-GY026
Recurrent
3
Ovarian
2
Primary
3
Recurrent
3
Platinum Sensitive
1
Platinum Refractory
Platinum Resistant
2
Supportive Care/Imaging
Prostate and Urologic Cancers
Bladder/Urothelial
1
Localized
Adjuvant
Bladder Sparing
Neoadjuvant
Metastatic
4
1st Line
2nd Line +
1
Non-Muscle Invasive
Kidney
Metastatic
2
1st Line
2
2nd Line +
1
Non-Metastatic
1
Preventative, Supportive Care, and Wellness
Prostate
2
Biochemical Relapsed
Castrate Resistant
Hormone Sensitive
2
NRG-GU011
Localized
1
Metastatic Castrate Resistant
4
1st Line
2nd Line +
6
Metastatic Hormone Sensitive
1
Testes/Germ Cell
1
Testicular
1st Line
2nd Line+
Head and Neck
1
NEOGENE-NT-175-201
Phase I
OPEN TO ACCRUAL
Larynx
4
Lip, Oral Cavity, and Pharynx
5
Non-Squamous Cell
Salivary Gland
1
Squamous Cell
4
Recurrent/Metastatic
5
Resectable
Unresectable
Thyroid
1
Preventative, Supportive Care, and Wellness
1
Hematologic / Blood Related Cancers
10
ALLIANCE-MM1MDS-A01
Phase II
OPEN TO ACCRUAL
ECOG-EA4232
Phase III
OPEN TO ACCRUAL
ICHNOS-ISB-2001-101
Phase I
OPEN TO ACCRUAL
IIT-AKHTAR-CILTA-TALQ
Phase I
OPEN TO ACCRUAL
INCYTE-INCA035784-101
Phase I
OPEN TO ACCRUAL
INCYTE-INCA-34176-254
Phase II
OPEN TO ACCRUAL
LILLY-J2N-MC-JZNY
Phase IV
OPEN TO ACCRUAL
MODERNA-MRNA-2808-P101
Phase I/II
OPEN TO ACCRUAL
SWOG-MM1OA-S03
Phase II
OPEN TO ACCRUAL
SWOG-MM1YA-S01
Phase II
OPEN TO ACCRUAL
Leukemia
21
MF/MPN
3
ALL
4
1 Treatment Naive
1
2 Relapsed/Refractory
3
AML
9
Relapsed/Refractory
3
Treatment Naive
7
APL
Cell Therapy
2
CLL
4
1 Treatment Naive
2 Relapsed/Refractory
4
CML
2
Treatment Naive
1
Relapsed/Refractory
1
MDS and CMML
4
1 Treatment Naive
2
2 Relapsed/Refractory
2
Transplant
1
Lymphoma
14
Cell Therapy
4
Hodgkins
Newly Diagnosed
Relapsed/Refractory
Non-Hodgkins
9
Newly Diagnosed
3
Burkitt
CLL
DLBCL
Follicular
2
Low Grade
LPL/WM
Mantle Cell
1
Marginal Zone
Other
Richter Syndrome
Transformed
Relapsed/Refractory
6
Burkitt
1
CLL
3
DLBCL
5
Follicular
4
Low Grade
LPL/WM
3
Mantle Cell
3
Marginal Zone
3
Other
1
Richter Syndrome
2
Transformed
2
Transplant
Multiple Myeloma
14
Amyloidosis
3
Cell Therapy
2
Newly Diagnosed
2
Relapsed/Refractory
4
Transplant
Other Blood Related
4
Amyloidosis
2
Preventative, Supportive Care, and Wellness
Fate
Sarcoma
1
POLARIS-2022-001-ARGSARC
Phase III
OPEN TO ACCRUAL
Osteosarcoma
1
Other Cancer (Desmoid, Gist, etc.)
2
Soft Tissue Sarcoma
3
Adjuvant
Metastatic
2
Supportive Care Trials
1
Skin
Melanoma
1
Adjuvant
Metastatic
2
Resected
Non Melanoma Skin Cancer
Adjuvant
Metastatic
2
Preventative, Supportive Care, and Wellness
1
Thoracic and Chest Cancers
3
AZ-D516NC00001-TROPION-LUNG14
Phase III
OPEN TO ACCRUAL *
IIT-GORE-REDIRICT
Phase II
OPEN TO ACCRUAL
NEOGENE-NT-112-301
Phase I
OPEN TO ACCRUAL
Lung
3
NSCLC
6
Resected
Stage I
Stage II
Stage III
1
Stage IV
8
Small Cell
4
Other Respiratory
Preventative, Supportive care, and Wellness
Early Phase / Multiple Disease Site
8
CARNABIOSCIENCES-C1763102
Phase I
OPEN TO ACCRUAL
DAIICHI-SANKYO-DS3201-343
Phase I
OPEN TO ACCRUAL
DAIICHI-SANKYO-DS3939-077
Phase I/II
OPEN TO ACCRUAL
ICHNOS-ISB-2001-101
Phase I
OPEN TO ACCRUAL
IIT-GORE-REDIRICT
Phase II
OPEN TO ACCRUAL
STEMLINE-MEN2312-01
Phase I
OPEN TO ACCRUAL
TERREMOTO-TER-2013-C01
Phase I/II
OPEN TO ACCRUAL
TEVA-TV56278-ONC-10203
Phase I
OPEN TO ACCRUAL
Hematologic Malignancies
12
Early Phase Team
11
Plasma Cell Disorders
4
Multiple Myeloma
2
Relapsed/Refractory
2
3 or more prior lines
1
1-5 prior lines
1
Exhausted all SOC options
2 or more prior lines
1-3 prior lines
Newly Diagnosed
Amyloidosis
2
Lymphoma
4
NHL
3
Follicular
3
Relapsed/Refractory
3
2 or more prior lines
1
DLBCL
3
Relapsed/Refractory
3
2 or more prior lines
1
3 or more prior lines
First line only
Treatment Naïve
MCL
3
Relapsed/Refractory
3
2 or more prior lines
1
3 or more prior lines
MZL
3
Relapsed/Refractory
3
2 or more prior lines
1
CLL/SLL
3
Relapsed/Refractory
3
2 or more prior lines
1
Transformed/Richter
2
Relapsed/Refractory
2
2 or more prior lines
1
T-Cell Lymphoma
Relapsed/Refractory
2 or more prior lines
1 or more prior lines
WM
1
2 or more prior lines
HL
Leukemia
6
AML
3
Relapsed/Refractory
3
1 or more prior lines
Exhausted all SOC options
1
Treatment Naive
ALL
1
Relapsed/Refractory
1
Post Frontline + Salvage
1 or more prior lines
1
CLL
2
CML
MDS
Relapsed/Refractory
MPN
1
BMT/Cell Therapy Team
1
Hematology Team
Solid Tumor
9
Brain and Spine
1
1st Line
2nd Line
3rd Line
4 Lines or Greater
Breast
2
1st line
2nd line
4
Cell Therapy
Endocrine
Eye/Orbital
GI
7
Gynecologic
5
Prostate and Urologic
6
Head and Neck
6
Hematologic
Sarcoma
2
Skin (Melanoma & non-melanoma)
2
Thoracic/Chest
10
Precision Medicine
1
Multiple Diseases
7
Precision Medicine
1
IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
Preventative, Supportive Care, and Wellness
1
ALLIANCE-A151804
Phase N/A
OPEN TO ACCRUAL
Pediatric Oncology
14
BCC-014-DFMO
Phase II
OPEN TO ACCRUAL
BCC-015
Phase II
OPEN TO ACCRUAL *
COG-AALL1732
Phase III
OPEN TO ACCRUAL
COG-AALL1821
Phase II
OPEN TO ACCRUAL
COG-AAML1831
Phase III
OPEN TO ACCRUAL
COG-ACNS1821
Phase I/II
OPEN TO ACCRUAL
COG-ACNS1833
Phase III
OPEN TO ACCRUAL
COG-ACNS2031
Phase III
OPEN TO ACCRUAL
COG-AGCT1531
Phase III
OPEN TO ACCRUAL
COG-AHOD2131
Phase III
OPEN TO ACCRUAL
COG-ALLIANCE-AGCT1532-P3BEP
Phase III
OPEN TO ACCRUAL *
COG-ANBL1531
Phase III
OPEN TO ACCRUAL
COG-AREN1921
Phase II
OPEN TO ACCRUAL *
PBMTC-ONC1401
Phase II
OPEN TO ACCRUAL
Bone Marrow Transplant and Cellular Therapy
1
PBMTC-ONC1401
Phase II
OPEN TO ACCRUAL
Brain and Spinal Cord Tumors
3
COG-ACNS1821
Phase I/II
OPEN TO ACCRUAL
COG-ACNS1833
Phase III
OPEN TO ACCRUAL
COG-ACNS2031
Phase III
OPEN TO ACCRUAL
Early Phase Trials (Phase I and II)
5
BCC-014-DFMO
Phase II
OPEN TO ACCRUAL
BCC-015
Phase II
OPEN TO ACCRUAL *
COG-AALL1821
Phase II
OPEN TO ACCRUAL
COG-AREN1921
Phase II
OPEN TO ACCRUAL *
PBMTC-ONC1401
Phase II
OPEN TO ACCRUAL
Late Effects and Supportive Studies
Leukemia
4
COG-AALL1732
Phase III
OPEN TO ACCRUAL
COG-AALL1821
Phase II
OPEN TO ACCRUAL
COG-AAML1831
Phase III
OPEN TO ACCRUAL
PBMTC-ONC1401
Phase II
OPEN TO ACCRUAL
Lymphoma
1
COG-AHOD2131
Phase III
OPEN TO ACCRUAL
Non-Malignant Disorders
Precision Medicine
1
COG-ACNS1833
Phase III
OPEN TO ACCRUAL
Solid Tumors
6
BCC-014-DFMO
Phase II
OPEN TO ACCRUAL
BCC-015
Phase II
OPEN TO ACCRUAL *
COG-AGCT1531
Phase III
OPEN TO ACCRUAL
COG-ALLIANCE-AGCT1532-P3BEP
Phase III
OPEN TO ACCRUAL *
COG-ANBL1531
Phase III
OPEN TO ACCRUAL
COG-AREN1921
Phase II
OPEN TO ACCRUAL *
Search
Should appear
Must not appear
Search
